Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America

Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America BRIEF REPORT Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America Oscar Arrieta,* Andre ´s Felipe Cardona,†‡ Guillermo Federico Bramuglia,§ Aly Gallo,¶ Alma D. Campos-Parra,* Silvia Serrano,‡ Marcelo Castro, Alejandro Avile ´s,* Edgar Amorin,# Ricardo Kirchuk,** Mauricio Cuello,†† Jose ´ Borbolla,‡‡§§ Omar Riemersma, Henry Becerra,† and Rafael Rosell,¶¶ on behalf of the CLICaP (Latin American Consortium for the Investigation of Lung Cancer) and absence of KRAS mutations. Overall response rate to tyrosine Introduction: Frequency of mutations in EGFR and KRAS in non- kinase inhibitors in EGFR-mutated patients (n  56) was 62.5% small cell lung cancer (NSCLC) is different between ethnic groups; (95% CI 50 –75) with a median overall survival of 16.5 months however, there is no information in Latin-American population. (95% CI 12.4 –20.6). Methods: A total of 1150 biopsies of NSCLC patients from Latin Conclusions: Our findings suggest that the frequency of EGFR America (Argentina, Colombia, Peru, and Mexico) were used ex- mutations in Latin America lies between that of Asian and Cauca- tracting genomic DNA to perform direct sequencing of EGFR gene sian populations and therefore support the genetic heterogeneity of (exons 18 and 21) and KRAS gene in 650 samples. In Mexico, NSCLC around http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America

Journal of Thoracic Oncology , Volume 6 (11) – Nov 1, 2011

Loading next page...
 
/lp/wolters-kluwer-health/genotyping-non-small-cell-lung-cancer-nsclc-in-latin-america-lAsWb1lokp

References (19)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e31822f655f
pmid
22005474
Publisher site
See Article on Publisher Site

Abstract

BRIEF REPORT Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America Oscar Arrieta,* Andre ´s Felipe Cardona,†‡ Guillermo Federico Bramuglia,§ Aly Gallo,¶ Alma D. Campos-Parra,* Silvia Serrano,‡ Marcelo Castro, Alejandro Avile ´s,* Edgar Amorin,# Ricardo Kirchuk,** Mauricio Cuello,†† Jose ´ Borbolla,‡‡§§ Omar Riemersma, Henry Becerra,† and Rafael Rosell,¶¶ on behalf of the CLICaP (Latin American Consortium for the Investigation of Lung Cancer) and absence of KRAS mutations. Overall response rate to tyrosine Introduction: Frequency of mutations in EGFR and KRAS in non- kinase inhibitors in EGFR-mutated patients (n  56) was 62.5% small cell lung cancer (NSCLC) is different between ethnic groups; (95% CI 50 –75) with a median overall survival of 16.5 months however, there is no information in Latin-American population. (95% CI 12.4 –20.6). Methods: A total of 1150 biopsies of NSCLC patients from Latin Conclusions: Our findings suggest that the frequency of EGFR America (Argentina, Colombia, Peru, and Mexico) were used ex- mutations in Latin America lies between that of Asian and Cauca- tracting genomic DNA to perform direct sequencing of EGFR gene sian populations and therefore support the genetic heterogeneity of (exons 18 and 21) and KRAS gene in 650 samples. In Mexico, NSCLC around

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Nov 1, 2011

There are no references for this article.